Parth Doshi·Apr 22Your Genome Sequencing Lab is Leaving Diagnoses on the Table — Here’s the MathFor every 100 patients you sequence and can’t diagnose, 5 to 15 of them already have the answer sitting in your pipeline. You just have not…A response icon1A response icon1
Parth Doshi·Mar 1710,000 Cells Don’t Replace 3 PatientsThe pseudoreplication trap quietly inflating false discoveries in single-cell RNA-seq — and how rigorous teams avoid itA response icon1A response icon1
Parth Doshi·Mar 13Why Your RNA-seq Pathway Plots Aren’t Validated (And What To Do Instead)How database overlap, expression bias, and background selection distort enrichment results
Parth Doshi·Mar 3RNA-seq Is Compositional Data — And Why That Quiet Detail Can Break Your BiomarkersHow relative transcript measurements and normalisation assumptions can distort differential expression, machine learning models, and…
Parth Doshi·Feb 26The Normalisation Paradox: How One Line of Code Flips Your Biological DiscoveryYou think you have just found a clean lung cancer biomarker. In your TPM-normalised RNA-seq data, the gene is beautifully upregulated in…
Parth Doshi·Feb 12The P-value Trap: Why Your Differential Expression Results May Be LyingPractical ways to avoid statistical pitfalls in RNA-seq analysis
Parth Doshi·Jan 28Why 3 Replicates Isn’t Enough for RNA-seq (Power, False Positives, and What’s Still Possible)You spent $500 on RNA-seq and got back a list of 500 “significant” genes.A response icon1A response icon1
Parth Doshi·Jan 15Batch Effects in RNA-seq: The Hidden Threat to Your AnalysisWhy your “novel biomarker” might be a “Tuesday effect” and the R code to fix it.